Profits drive rising prices for MS drugs, say industry executives
U.S. Medicare patients with multiple sclerosis often pay, on average, nearly $ 7,000 out of pocket to treat their condition each year. And even though drug companies have provided no new treatment breakthroughs, the price of these disease-modifying medications has been rising by 10 to 15% each year for the past decade. To find out… Read More »